Maximilian Moersdorf, Jan G P Tijssen, Nassir F Marrouche, Harry J G M Crijns, Angelika Costard-Jaeckle, Leonard Bergau, Gerhard Hindricks, Nikolaos Dagres, Samuel Sossalla, Rene Schramm, Henrik Fox, Thomas Fink, Mustapha El Hamriti, Vanessa Sciacca, Frank Konietschke, Volker Rudolph, Jan Gummert, Philipp Sommer, Christian Sohns
BACKGROUND: The CASTLE-HTx trial demonstrated the benefit of atrial fibrillation (AF) ablation compared to medical therapy in decreasing mortality, need for left ventricular assist device (LVAD) implantation or heart transplantation (HTx) in patients with end-stage heart failure (HF). OBJECTIVES: The aim of this analysis was to identify risk factors related to adverse outcomes in patients with end-stage HF and to assess the impact of ablation. METHODS: The CASTLE-HTx protocol randomized 194 patients with end-stage HF and AF to ablation versus medical therapy...
April 6, 2024: Heart Rhythm: the Official Journal of the Heart Rhythm Society